EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES
COMMONWEALTH OF MASSACHUSETTS
OFFICE OF MEDICAID
ONE ASHBURTON PLACE, BOSTON, MA 02108
MAURA T. HEALEY KATHLEEN E. WALSH
GOVERNOR SECRETARY
KIMBERLEY DRISCOLL MIKE LEVINE
LIEUTENANT GOVERNOR ASSISTANT SECRETARY
FOR MASSHEALTH
September 20, 2024
Chair Michael J. Rodrigues Chair Aaron M. Michlewitz
Senate Committee on Ways and Means House Committee on Ways and Means
State House, Room 212 State House, Room 243
Boston, MA 02133 Boston, MA 02133
Chair Cindy F. Friedman Chair John J. Lawn, Jr.
Joint Committee on Health Care Financing Joint Committee on Health Care Financing
State House, Room 313 State House, Room 236
Boston, MA 02133 Boston, MA 02133
Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:
Chapter 28 of the Acts of 2023 line item 4000-0300 requires the Executive Office of Health and Human
Services to submit a quarterly report including the projected total costs for the next fiscal year of
pharmaceutical pipeline drugs identified by the executive office and expected to be made available for
utilization within a 12-month period.
The Executive Office of Health and Human Services has identified 67 pipeline market entries from 74
manufacturers expected to be made available for utilization between July 1st 2024 and June 30th 2025. The
estimated spend on the expected utilization of these products for all MassHealth members (including
those enrolled with managed care) is approximately $8.4M for the same time period. The prior quarterly
reported estimated a spend of $13.9M based on the addition of 68 pipeline market entries from 73
manufacturers. Cell therapies and various oncologic therapies remain the top drivers in spend. The
decrease in spend from the previous report is largely due to the approval of two additional gene therapies.
Please contact Sarah Nordberg at Sarah.Nordberg@mass.gov should you have any questions about this
report.
Sincerely,
Mike Levine
cc: Kathleen E. Walsh